Ambu AS 2023 AR2
The report highlights Ambu's strong progress in the 2022/23 fiscal year under its ZOOM IN strategy, achieving 7.6% organic revenue growth and expanding its EBIT margin before special items to 6.3%. In sustainability, the company launched the world's first endoscope made with bioplastics, the aScope Gastro Large, and committed to using bioplastics in all single-use endoscopes shipped from early 2024/25. Ambu also submitted its 2030 emission reduction targets to the Science-Based Targets initiative (SBTi). Financially, the company significantly improved its free cash flow to DKK 192m and reduced its financial leverage to 0.7x EBITDA.
Company: Ambu AS
Sector: Health Care
Country: Denmark
Year: 2023
Type: AR2
Pages: 181
Ambu AS
Annual Report
The report highlights Ambu's strong progress in the 2022/23 fiscal year under its ZOOM IN strategy, achieving 7.6% organic revenue growth and expanding its EBIT margin before special items to 6.3%. In sustainability, the company launched the world's first endoscope made with bioplastics, the aScope Gastro Large, and committed to using bioplastics in all single-use endoscopes shipped from early 2024/25. Ambu also submitted its 2030 emission reduction targets to the Science-Based Targets initiative (SBTi). Financially, the company significantly improved its free cash flow to DKK 192m and reduced its financial leverage to 0.7x EBITDA.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Oct 1, 2022 - Sep 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees